It is with much enthusiasm we announce that Mallinckrodt Pharmaceuticals reached an agreement to divest and transfer the IND application of Adrabetadex to the company, Mandos, LLC. With this news, it is their goal to continue to develop the therapy and provide access of Adrabetadex up to an additional two years to eligible patients. Here is a link to the press release.
We understand that there may be a lot of questions that we do not have answers to as of yet. The agreement and the closing of the transaction is subject to approval of the U.S. Bankruptcy Court for the District of Delaware as part of Mallinckrodt’s Chapter 11 filing. We will be working with Mallinckrodt Pharmaceuticals and Mandos, LLC to identify a time for you to speak with them to learn more about their development plan for Adrabetadex.
This has been a very tough journey, especially over the past few months, but we are very excited that Mandos will be picking up the reins and will be working with the NPC community and the FDA to ultimately get Adrabetadex approved.
Thank you and more information will come soon.
Sean and Cindy